GSK management outlined a long-term turnaround strategy at Bernstein’s 23rd Annual Pan-European Strategic Decisions Conference. The plan focuses on accelerating R&D, launching new products, and reducing operational complexity.
This initiative counters earnings pressure from the patent expiry of the HIV drug dolutegravir later this decade. The company will reinvest most of its £1.9 billion in cost savings into its development pipeline.
Management specifically targets growth in oncology to maintain stable margins through the 2028-2030 patent cliff period. GSK concurrently executed a $6.5 billion bond offering in U.S. markets to fund these initiatives.